Prime Medicine, Inc. (PRME) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -196.52M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 146.20M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-196.52M | (m) | (m) | $146.20M | (m) | (m) |
| 2026-03-31 | $-206.61M | (m) | (m) | $154.18M | (m) | (m) |
| 2025-12-31 | $-208.35M | $4.63M | (m) | $160.64M | (m) | -4498.06% |
| 2025-09-30 | $-203.96M | $5.98M | (m) | $160.03M | (m) | -3412.48% |
| 2025-06-30 | $-204.22M | $4.96M | (m) | $156.38M | (m) | -4116.57% |
| 2025-03-31 | $-206.52M | $3.85M | (m) | $158.08M | (m) | -5369.68% |
| 2024-12-31 | $-202.47M | $2.98M | (m) | $155.29M | (m) | -6787.36% |
| 2024-09-30 | $-226.29M | (m) | (m) | $162.64M | (m) | (m) |
| 2024-06-30 | $-223.51M | (m) | (m) | $163.27M | (m) | (m) |
| 2024-03-31 | $-213.10M | (m) | (m) | $154.80M | (m) | (m) |
| 2023-12-31 | $-204.79M | (m) | (m) | $147.91M | (m) | (m) |
| 2023-09-30 | $-175.44M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-155.63M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-136.68M | (m) | (m) | $103.93M | (m) | (m) |
| 2022-12-31 | $-116.54M | $0.00 | (m) | $86.72M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-84.47M | $0.00 | (m) | $70.55M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-932.00K | $5.21M | (m) | $2.98M | (m) | -17.89% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |